Zobrazeno 1 - 10
of 60
pro vyhledávání: '"L. Garzanova"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Annals of the Rheumatic Diseases. 81:1460.2-1460
BackgroundThe low prevalence of pregnancy in women with systemic sclerosis (SSc) is due to multi-factorial causes, including premature ovarian insufficiency (POI). Anti-Mullerian hormone (AMH) is one of the primary parameters for assessing reproducti
Autor:
O. Ovsyannikova, O. Koneva, L. Garzanova, L. P. Ananyeva, A. Khelkovskaia-Sergeeva, R. Shayakhmetova, O. Desinova, M. Starovoytova
Publikováno v:
Annals of the Rheumatic Diseases. 81:1791.2-1791
BackgroundInterstitial lung disease (ILD) is one of the most relevant extra-articular manifestations of rheumatic diseases resulting in a substantial increase in morbidity and mortality. High-resolution computed tomography (HRCT), which is the curren
Autor:
O. Koneva, L. Garzanova, O. Ovsyannikova, N. Kovaleva, L. P. Ananyeva, O. Desinova, M. Starovoytova, R. Shayakhmetova
Publikováno v:
Annals of the Rheumatic Diseases. 81:1490.2-1490
BackgroundHRCT is the gold standard for confirming ILD.However,the role of HRCT for estimating the effectiveness of therapy is not determined in full.ObjectivesTo assess the dynamics of X-ray changes and PFTs during IST in pts with SSc and different
Autor:
L. Garzanova, L. P. Ananyeva, O. Koneva, O. Desinova, O. Ovsyannikova, M. Starovoytova, R. Shayakhmetova, A. Khelkovskaia-Sergeeva
Publikováno v:
Annals of the Rheumatic Diseases. 81:1479.2-1479
BackgroundRituximab (RTX) has shown itself as an effective option in treatment of interstitial lung disease associated with systemic sclerosis (ILD-SSc). However, there is not enough data on the effect of rituximab biosimilars in patients (pts) with
Autor:
O. Ovsyannikova, O. Koneva, L. Garzanova, S. Glukhova, L. P. Ananyeva, A. Khelkovskaia-Sergeeva
Publikováno v:
Annals of the Rheumatic Diseases. 81:1792.1-1792
BackgroundPulmonary disease is one of the most relevant with interstitial lung disease (ILD) being one of the most frequents forms of involvement with resultant worsening of morbidity and mortality in disorders such as systemic sclerosis (SSc), rheum
Autor:
L. P. Ananyeva, L. Garzanova, S. Glukhova, O. Desinova, O. Koneva, M. Starovoytova, R. Shayakhmetova, O. Ovsyannikova
Publikováno v:
Annals of the Rheumatic Diseases. 81:727.1-727
BackgroundRituximab (RTX) is considered as one of the effective options for the treatment of interstitial lung disease associated with systemic sclerosis (ILD-SSc) [1]. Factors that affect the effect of RTX therapy are not well investigated.Objective
Autor:
M. Starovoytova, O. Desinova, L. P. Ananyeva, R. Shayakhmetova, A. Khelkovskaia-Sergeeva, O. Koneva, L. Garzanova, O. Ovsyannikova
Publikováno v:
Annals of the Rheumatic Diseases. 81:1494.2-1494
BackgroundInterstitial lung disease (ILD) is one of the most common and severe manifestations of connective tissue diseases, such as systemic scleroderma (SSc), dermato- and polymyositis (DM/PM), mixed connective tissue disease (MCTD), etc.Objectives
Autor:
O. Koneva, L. Garzanova, S. Glukhova, O. Desinova, L. P. Ananyeva, O. Ovsyannikova, M. Starovoytova
Publikováno v:
Annals of the Rheumatic Diseases. 81:1491.1-1491
BackgroundImmunosuppressants (IS) is considered as a drug of choice for the treatment of interstitial lung disease (ILD) in the patients with systemic sclerosis (SSc). However, the IS use leads to rather limited and transient improvement of the pulmo
Autor:
L. Garzanova, L. P. Ananyeva, O. Koneva, O. Ovsyannikova, O. Desinova, M. Starovoytova, R. Shayakhmetova, A. Khelkovskaia-Sergeeva
Publikováno v:
Annals of the Rheumatic Diseases. 81:1480.1-1480
BackgroundDecrease of immunoglobulin G (IgG) could often be observed during rutuximab (RTX) therapy in systemic sclerosis (SSc) and other autoimmune diseases. Lower lever of IgG could be associated with an increased risk of secondary infectious compl